相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
Anja Schork et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
Megumi Oshima et al.
DIABETOLOGIA (2019)
Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
James L. Rosenzweig et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Intensive Glucose Control in Patients with Type 2 Diabetes-15-Year Follow-up
Peter D. Reaven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Shih-Chieh Shao et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
Yehuda Handelsman et al.
DIABETES OBESITY & METABOLISM (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
Concetta Irace et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
M. V. Karg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Timothy M. E. Davis et al.
DIABETES OBESITY & METABOLISM (2018)
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study
Russell Scott et al.
DIABETES OBESITY & METABOLISM (2018)
Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity
Sadiya S. Khan et al.
JAMA CARDIOLOGY (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes
Alexandra K. Lee et al.
DIABETES CARE (2018)
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
Fumika Shigiyama et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity
Christos N. Joannides et al.
DIABETES OBESITY & METABOLISM (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
K. Ogurtsova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes
Tushar P. Patel et al.
HEART FAILURE REVIEWS (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial
Jan Bolinder et al.
LANCET (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes
Guntram Schernthaner et al.
POSTGRADUATE MEDICINE (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Catherine Gorst et al.
DIABETES CARE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Excess Mortality among Persons with Type 2 Diabetes
Mauro Tancredi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Uric Acid Levels, Kidney Function, and Cardiovascular Mortality in US Adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002
Michelle C. Odden et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial
Yoichiro Hirakawa et al.
DIABETES CARE (2014)
Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan
Akiko Muramoto et al.
OBESITY RESEARCH & CLINICAL PRACTICE (2014)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
Y. G. Kim et al.
DIABETOLOGIA (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Severe Hypoglycemia and Risks of Vascular Events and Death.
Sophia Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
Giovanni Targher et al.
DIABETES CARE (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
